Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 176 In stock
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
ATR [12]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM 1.8 μM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 NUPre441T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7Kb3JtOi53IN88US=> MUWxMVQh\A>? M1:0VWROW09? MXXlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> MVeyOVQ6ODN6Mx?=
H1703 NE\CcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\JXmkzNjVizszN NXL5VYxbOS12IHS= NIXBfnJFVVOR MXXlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> MXuyOVQ6ODN6Mx?=
HUVECs NFz4ZlZEgXSxdH;4bYNqfHliQYPzZZk> NVjkeGVoOTByIH7N NE[1VZEzPCCq NH72W2hifHSnboXheIV{KHSqZTDhZpJw\2G2aY\lJIVn\mWldIOgc4Yh[2GueXPvd4lvKG:wIG\STU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? MmXpNlU1PTBzOE[=
APRE-19 M2HhTWFxd3C2b4Ppd{BCe3OjeR?= MVO1JO69VQ>? NVflSGRFOjRiaB?= NGS5b3li[m:uaYPo[ZMhTkycLX3l[IlifGWmIIDyc{1{fXK4aY\hcE9idnSrLXHwc5B1d3OrczDhZ5Rqfmm2eR?= MV6yOVMzQTZzNx?=
MDA-MB-231 MUfBdI9xfG:|aYOgRZN{[Xl? M4\5U|HDqM7:TdMg NG\aWFI1QCCq NGnOT2RFVVOR NGrWbZNl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhfHKnYYTl[EB4cXSqIEK1JO69VSCxZjDGNUBweiCIMjFCpC=> NIP0SnYzPTNyMEmzNi=>
MCF7 MnPRSpVv[3Srb36gRZN{[Xl? NXjQcJV4OTByIH7N MoXENlQhcA>? NFPkS3dmdGmvaX7heIV{KEV{LXnu[JVk\WRiQWLFMWx2[yCjY4Tpeol1gQ>? MoSyNlUyPzJ3NUe=
HT-29  Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P3Z|EvPcLiwsXN M4LpTFk3KGh? Mlnj[IVkemWjc3XzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDpcohq[mm2ZXSgZpkhU1mQQR?= NEn6XnIzPTBzMkGyNy=>
MO59K  NYT1ZoI5S3m2b4TvfIlkcXS7IFHzd4F6 M2[3V|XDqM7:TR?= M1nSN|ch\A>? MXjEUXNQ MlW5[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw MoXMNlQ6PTN3NkG=
MO59J NEOzXmFEgXSxdH;4bYNqfHliQYPzZZk> MkGxOeKh|ryP NF31TI44KGR? MmHRSG1UVw>? NUTPSY5x\W6qYX7j[ZMhfGinIHP5eI91d3irY3n0fUBw\iCndH;wc5Nq\GVib4KgZ4l{eGyjdHnu M1\oNFI1QTV|NU[x
MO59K  MmnkRZBweHSxc3nzJGF{e2G7 MmjZNVAh|ryP MUGyOEBp M3fp[GROW09? MmL4bY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv NYrTelh3OjR7NUO1OlE>
MO59J NH;lUlRCeG:ydH;zbZMhSXO|YYm= MknaNVAh|ryP NXm4Z5U4OjRiaB?= M{n6NmROW09? M3e3Solv[3KnYYPld{B1cGViRGPCJIxmfmWuIHnu[JVk\WRiYomg[ZRweG:|aXTlJI9zKGOrc4DsZZRqdg>? NGTmbYszPDl3M{W2NS=>
HepG2 NVL4SodbTnWwY4Tpc44hSXO|YYm= NUfiTm84OTByIH7N NHqzV3UxNjViaB?= NXvhWXlsTE2VTx?= MoHhZoxw[2u|IF3BMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> MYWyOFg3OzN3MB?=
A549  M1\wVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfKbFZ2OyEEtV5CpC=> NVrkdIE1OiCq M1vpU5N2eHC{ZYPz[ZMheGWvZYTy[Zhm\C2rbnT1Z4VlKEGtdDDhcoQhT1ONM98yJIFkfGm4YYTpc44tKFNvcHjhd4Uh[XK{ZYP0MEBk\WyuIHHwc5B1d3OrczDhcoQh[2G|cHHz[U0{KGGldHn2ZZRqd25? MmXoNlQ5PDd6NkO=
A549  MVnGeY5kfGmxbjDBd5NigQ>? MXOxNOKh|ryvwrC= NWKzb4xpOTZiaB?= NI\H[ldFVVOR MV\tc4R2dGG2ZYOgeIhmKEmDVjDy[ZBtcWOjdHnvckBidmRiY3H1d4V{KHKndHXueIlwdiCxZjDOVEBqdiC2aHWgcpVkdGW3cz6= Mme2NlQ5ODJzMUG=
SK-N-LO MlX2SpVv[3Srb36gRZN{[Xl? M3L5OFExOCCwTR?= M3vo[|AvPSCq NVHOT3Vy\GWlcnXhd4V{KHSqZTDzeIlufWyjboSg[YZn\WO2czDv[kBud3KyaHnu[UBwdiCDa4SgdIhwe3Cqb4L5cIF1cW:w M4PWdFI1PjV2NkC2
HL-60 NF\qcm9HfW6ldHnvckBCe3OjeR?= MnnDNE4yyqEQvF2= MkPvO|IhcA>? MU\icI9kc3NiZHHzZZRqdmmkLXnu[JVk\WRiY3XscEBlcW[oZYLlcpRq[XSrb36= MlPqNlQ3ODd{N{O=
HepG2  NX;DOWhITnWwY4Tpc44hSXO|YYm= NEHZXlIzODBibl2= NGfDUYMxNjViaB?= NWPBTphr[XS2ZX71ZZRmeyCIb4jPJJBpd3OyaH;yfYxifGmxbh?= Ml\uNlQ2OzVzOUK=
H520 NYOzOpY{TnWwY4Tpc44hSXO|YYm= M3;RUFExyqEQvF2= MVmxJIg> M2fSOmROW09? MVPk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= MVGyOFQ1Pzl|NR?=
H1975 MkXsSpVv[3Srb36gRZN{[Xl? MVexNOKh|ryP NUC2PIh3OSCq NV7ZdmNnTE2VTx?= NED4eVhl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> NXXhTGRoOjR2NEe5N|U>
MG-63 NFvPemNCeG:ydH;zbZMhSXO|YYm= NHS4TpEyOCEEtV2= MoLvNVIhcA>? M{LyR4VvcGGwY3XzJGRRNWmwZIXj[YQh[XCxcITvd4l{ MUOyOFM2QDNyMR?=
5637 NGTxS3RCeG:ydH;zbZMhSXO|YYm= NXzRWmlyOTEEoN88US=> NYLiUJJGPDBibXnu Moq1doV3\XK|ZYOgdFIyX0GIMTDlfJBz\XO|aX;uMEBETEtiZYjwdoV{e2mxbjygZY5lKGOnbHygbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KG[3Y3;p[IFv MY[yOFM{Ozh4OB?=
HEK-293 M{XkNmZ2dmO2aX;uJGF{e2G7 NH;qU5kyPTCwTR?= NIizOGkyPiCq M2XEVmROW09? NUH6WJJW\GWlcnXhd4V{KEOUVDDhZ5Rqfmm2eR?= NVr6OGxkOjR|MkSzOlY>
SW480  MYXGeY5kfGmxbjDBd5NigQ>? M3;oXFE2OG6P NW\T[np2OjBiaB?= MnXzSG1UVw>? Mn;sdoVlfWOnczDj[YxtfWyjcjDhZ4N2dXWuYYTpc44hd2ZizsKtZ4F1\W6rbh?= M3nQXVI1OzJ2M{[2
HepG2 MVLGeY5kfGmxbjDBd5NigQ>? MWOxNFAhdk1? MUeyOEBp NF;mSIxifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= M3mxR|I1Ojl5NUGw
HCT 116  NH3Ldm9HfW6ldHnvckBCe3OjeR?= NWf2dZVmOTByIH7N NIjGN4czPCCq NW\YVJJM[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= NIOzcG8zPDJ7N{WxNC=>
BEL/FU NFHlfoRHfW6ldHnvckBCe3OjeR?= MXGxJI1O NFHBPGgzPCCq M{HPZYRm[3KnYYPld{Bxem:2ZXnuJIxmfmWuczDv[kB1cGViUFmzT{9Cc3RicHH0bJdigQ>? MnTSNlQzOzJyOUm=
Huh7  NF[4[oxHfW6ldHnvckBCe3OjeR?= MlrQN:Kh|ryP MnP6NUBp NXzUSXZHemWmdXPld{B1cGVidnnyeZMh\W62comgbY51dyC2aHWgZ4VtdHN? NYe5dHp7OjRzOESxPVY>
A-375 MV7BdI9xfG:|aYOgRZN{[Xl? NHLOWYg1NzhizszN MViyOEBp MmKx[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= MVuyOFEyOzF5Mx?=
A-375-TS  M{jpbGFxd3C2b4Ppd{BCe3OjeR?= NFm1eI81NzhizszN MnriNlQhcA>? M2rSVoVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= M{\GfFI1OTF|MUez
Mel-HO M4rFXGFxd3C2b4Ppd{BCe3OjeR?= Mm\NOE85KM7:TR?= NVixdo5LOjRiaB?= MoG5[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= MnzLNlQyOTNzN{O=
Mel-HO-TS NITPTXlCeG:ydH;zbZMhSXO|YYm= NFzWcos1NzhizszN MmjoNlQhcA>? Ml;I[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NVrLZWtDOjRzMUOxO|M>
MeWo MUTBdI9xfG:|aYOgRZN{[Xl? NEjFWZc1NzhizszN M3rLVlI1KGh? MljH[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= M{HDPVI1OTF|MUez
Mel-2a MnmxRZBweHSxc3nzJGF{e2G7 MYq0M|gh|ryP MnHjNlQhcA>? M3vrPYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NYTTe3BkOjRzMUOxO|M>
MDA-MB-231 NVjmOohUTnWwY4Tpc44hSXO|YYm= NU\WeHN3OOLCk{SwNEBvVQ>? NF3NVoc1KGh? Mlnmd5VxeHKnc4Pld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1[2T|IzQTB4MkW5
MDA-MB-231 MnvtSpVv[3Srb36gRZN{[Xl? NUnl[2FsPDByIH7N NXLhcm5yPCCq M2DXR4Rm[3KnYYPld{BOVVBvOTDhcoQhUUxvODDwdo91\WmwIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIC3ZVkzOjlyNkK1PS=>
Jurkat MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jIUFAvOjVvMT6yOUDPxE1? MlPJNlQwPDhiaB?= NXHiVYRPTE2VTx?= NH7HO4lqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= Mn3aNVk4PTdzOEW=
Namalwa M2XtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjpNE4zPS1zLkK1JO69VQ>? MUmyOE81QCCq NETBfGRFVVOR M3K4dYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ NFnINYQyQTd3N{G4OS=>
Jurkat NUnISW4ySXCxcITvd4l{KEG|c3H5 MVqwMlI2NTFwMkWg{txO Mlq0NlQwPDhiaB?= MXrEUXNQ NYjldGtKcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz MVKxPVc2PzF6NR?=
Namalwa NWXvRZQ6SXCxcITvd4l{KEG|c3H5 MVGwMlI2NTFwMkWg{txO NVKzOVZbOjRxNEigbC=> MXHEUXNQ MlnibY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy NVfSVFkxOTl5NUexPFU>
K562 Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jhb|I1KGh? MX\JR|UxRTJ3wsGwMlE1KG6P MXGxPVY3OjN4MR?=
SW1990 M3z3emZ2dmO2aX;uJGF{e2G7 MVuwMlAyNTFizszN NF:5bXoyKGh? MUDpcohq[mm2czDIRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NXS0PGZzOTl2NkmwNlA>
RT112  M16yUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVixNOKh|ryP NIX2NJkzPCCq M4\TZ2ROW09? MYjk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gS|IwVSClZXzsdy=> MUGxPFc5Pzh|Mh?=
MHG-U1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf0ZnUyOMLizszN MnvjNlQhcA>? NGHs[o5FVVOR Mnix[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJGczN01iY3XscJM> NWXPZlV{OTh5OEe4N|I>
SMMC-7721 NFnGTVZCeG:ydH;zbZMhSXO|YYm= NYLhNpY5OjBywrDuUS=> Mn\FNlQhcA>? M{DQV4lv[3KnYYPld{BEUFhvaX7keYNm\CCjcH;weI9{cXN? NXPLb3NrOTd3NUexPVE>
SMMC-7721 MWnGeY5kfGmxbjDBd5NigQ>? MoPzNlAxyqCwTR?= NYTEWpZyOjRiaB?= NFLpfIR2eC2{ZXf1cIF1\XNizsKxMFRIXDFiZYjwdoV{e2mxbh?= NGryfXAyPzV3N{G5NS=>
HeLa M3vzVmZ2dmO2aX;uJGF{e2G7 M324WlExOMLibl5CpC=> MnTDNUBp MXnhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJRz[W6|ZnXydolvKHKnY4njcIlv\yClb33wZZJ1dWWwdB?= MomyNVY5QTB7MUW=
MRC5VI Ml\4SpVv[3Srb36gRZN{[Xl? MmDzNVIvPSCvTR?= MlPzNE42KGh? NGKzRWdFVVOR M1LBOIFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NEPHdJQyPjJ{N{O5OC=>
AT5BIVA NEXBXlhHfW6ldHnvckBCe3OjeR?= Ml;ONVIvPSCvTR?= NHr1NnIxNjViaB?= M{jWZmROW09? NEXKNmFi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? M{WxU|E3OjJ5M{m0
M059J MXzGeY5kfGmxbjDBd5NigQ>? MV6xNk42KG2P M4\NfVAvPSCq NYn2O45XTE2VTx?= M1u0PYFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh MUGxOlIzPzN7NB?=
HeLa NUTodmg{TnWwY4Tpc44hSXO|YYm= MnfrNVIvPSCvTR?= NWXkO3R5OC53IHi= M2nUOmROW09? MUHhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NGr1OFEyPjJ{N{O5OC=>
N2a MX\BdI9xfG:|aYOgRZN{[Xl? NUC4U4ZWOC5zLUGwJO69VQ>? MoHwNkBp Ml;pbY5lfWOnczDk[YNz\WG|ZXSgZ4VtdCC4aXHibYxqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NVvuTXNGOTV6NEK3Olc>
Jurkat  MkK2T4lv[XOnIFHzd4F6 MnnKTWM2OCCxZjCyOEBvVQ>? NYi3U3RiOTV4NkS1NVk>

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5%DMSO+corn oil 11mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID